{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T17:58:22Z","timestamp":1787162302742,"version":"build-2736575974"},"reference-count":77,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2013,7,1]],"date-time":"2013-07-01T00:00:00Z","timestamp":1372636800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,7,1]],"date-time":"2013-07-01T00:00:00Z","timestamp":1372636800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001700","name":"Ministry of Education, Culture, Sports, Science and Technology","doi-asserted-by":"publisher","award":["22-5"],"award-info":[{"award-number":["22-5"]}],"id":[{"id":"10.13039\/501100001700","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003478","name":"Ministry of Health, Labour and Welfare","doi-asserted-by":"publisher","award":["23791009"],"award-info":[{"award-number":["23791009"]}],"id":[{"id":"10.13039\/501100003478","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003478","name":"Ministry of Health, Labour and Welfare","doi-asserted-by":"publisher","award":["24234567"],"award-info":[{"award-number":["24234567"]}],"id":[{"id":"10.13039\/501100003478","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009438","name":"National Center of Neurology and Psychiatry","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009438","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Autoimmunity Reviews"],"published-print":{"date-parts":[[2013,7]]},"DOI":"10.1016\/j.autrev.2013.03.005","type":"journal-article","created":{"date-parts":[[2013,3,26]],"date-time":"2013-03-26T09:31:26Z","timestamp":1364290286000},"page":"912-917","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":31,"title":["Mechanisms associated with the pathogenicity of antibodies against muscle-specific kinase in myasthenia gravis"],"prefix":"10.1016","volume":"12","author":[{"given":"Shuuichi","family":"Mori","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuhiro","family":"Shigemoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.autrev.2013.03.005_bb0005","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/S1568-9972(02)00146-5","article-title":"Autoantibodies to ion channels at the neuromuscular junction","volume":"2","author":"Lang","year":"2003","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2013.03.005_bb0010","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.neuron.2006.09.024","article-title":"Autoimmune channelopathies and related neurological disorders","volume":"52","author":"Vincent","year":"2006","journal-title":"Neuron"},{"key":"10.1016\/j.autrev.2013.03.005_bb0015","doi-asserted-by":"crossref","first-page":"2843","DOI":"10.1172\/JCI29894","article-title":"Myasthenia gravis: past, present, and future","volume":"116","author":"Conti-Fine","year":"2006","journal-title":"J Clin Invest"},{"key":"10.1016\/j.autrev.2013.03.005_bb0020","first-page":"5","article-title":"The emerging diversity of neuromuscular junction disorders","volume":"26","author":"Newsom-Davis","year":"2007","journal-title":"Acta Myol"},{"key":"10.1016\/j.autrev.2013.03.005_bb0025","doi-asserted-by":"crossref","first-page":"A377","DOI":"10.1016\/j.autrev.2011.11.001","article-title":"The role of gender and organ specific autoimmunity","volume":"11","author":"Nussinovitch","year":"2012","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2013.03.005_bb0030","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1038\/85520","article-title":"Auto-antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies","volume":"7","author":"Hoch","year":"2001","journal-title":"Nat Med"},{"issue":"9","key":"10.1016\/j.autrev.2013.03.005_bb0035","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1016\/j.autrev.2013.03.004","article-title":"Diagnosis and therapy of myasthenia gravis with antibodies to muscle-specific kinase","volume":"12","author":"Evoli","year":"2013","journal-title":"Autoimmun. Rev"},{"key":"10.1016\/j.autrev.2013.03.005_bb0040","first-page":"281","article-title":"Cloning and developmental expression of Nsk2, a novel receptor tyrosine kinase implicated in skeletal myogenesis","volume":"11","author":"Ganju","year":"1995","journal-title":"Oncogene"},{"key":"10.1016\/j.autrev.2013.03.005_bb0045","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/0896-6273(95)90146-9","article-title":"Receptor tyrosine kinase specific for the skeletal muscle lineage: expression in embryonic muscle, at the neuromuscular junction, and after injury","volume":"15","author":"Valenzuela","year":"1995","journal-title":"Neuron"},{"key":"10.1016\/j.autrev.2013.03.005_bb0050","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/S0092-8674(00)81251-9","article-title":"The receptor tyrosine kinase MuSK is required for neuromuscular junction formation in vivo","volume":"85","author":"DeChiara","year":"1996","journal-title":"Cell"},{"key":"10.1016\/j.autrev.2013.03.005_bb0055","doi-asserted-by":"crossref","first-page":"4993","DOI":"10.1242\/dev.02696","article-title":"LDL-receptor-related protein 4 is crucial for formation of the neuromuscular junction","volume":"133","author":"Weatherbee","year":"2006","journal-title":"Development"},{"key":"10.1016\/j.autrev.2013.03.005_bb0060","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.cell.2008.10.002","article-title":"Lrp4 is a receptor for Agrin and forms a complex with MuSK","volume":"135","author":"Kim","year":"2008","journal-title":"Cell"},{"key":"10.1016\/j.autrev.2013.03.005_bb0065","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.neuron.2008.10.006","article-title":"LRP4 serves as a coreceptor of agrin","volume":"60","author":"Zhang","year":"2008","journal-title":"Neuron"},{"key":"10.1016\/j.autrev.2013.03.005_bb0070","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1242\/dev.038711","article-title":"To build a synapse: signaling pathways in neuromuscular junction assembly","volume":"137","author":"Wu","year":"2010","journal-title":"Development"},{"key":"10.1016\/j.autrev.2013.03.005_bb0075","doi-asserted-by":"crossref","first-page":"2304","DOI":"10.1093\/brain\/awg223","article-title":"Clinical correlates with anti-MuSK antibodies in generalized seronegative myasthenia gravis","volume":"126","author":"Evoli","year":"2003","journal-title":"Brain"},{"key":"10.1016\/j.autrev.2013.03.005_bb0080","doi-asserted-by":"crossref","first-page":"1978","DOI":"10.1212\/01.WNL.0000065882.63904.53","article-title":"Clinical aspects of MuSK antibody positive seronegative MG","volume":"60","author":"Sanders","year":"2003","journal-title":"Neurology"},{"key":"10.1016\/j.autrev.2013.03.005_bb0085","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1212\/01.wnl.0000228225.23349.5d","article-title":"Anti-MuSK antibodies: correlation with myasthenia gravis severity","volume":"67","author":"Bartoccioni","year":"2006","journal-title":"Neurology"},{"key":"10.1016\/j.autrev.2013.03.005_bb0090","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1212\/01.wnl.0000254620.45529.97","article-title":"Clinical comparison of anti-MuSK- vs anti-AChR-positive and seronegative myasthenia gravis","volume":"68","author":"Deymeer","year":"2007","journal-title":"Neurology"},{"key":"10.1016\/j.autrev.2013.03.005_bb0095","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1111\/j.1468-1331.2007.01870.x","article-title":"Clinical and experimental features of MuSK antibody positive MG in Japan","volume":"14","author":"Ohta","year":"2007","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.autrev.2013.03.005_bb0100","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1196\/annals.1405.012","article-title":"Response to therapy in myasthenia gravis with anti-MuSK antibodies","volume":"1132","author":"Evoli","year":"2008","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.autrev.2013.03.005_bb0105","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1196\/annals.1405.005","article-title":"Clinical phenotype of muscle-specific tyrosine kinase-antibody-positive myasthenia gravis","volume":"1132","author":"Wolfe","year":"2008","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.autrev.2013.03.005_bb0110","doi-asserted-by":"crossref","first-page":"53","DOI":"10.3988\/jcn.2009.5.2.53","article-title":"Muscle-specific receptor tyrosine kinase antibody positive myasthenia gravis current status","volume":"5","author":"Oh","year":"2009","journal-title":"J Clin Neurol"},{"key":"10.1016\/j.autrev.2013.03.005_bb0390","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1002\/mus.21533","article-title":"Clinical findings in MuSK-antibody positive myasthenia gravis: a U.S. experience","volume":"41","author":"Pasnoor","year":"2010","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.autrev.2013.03.005_bb0120","doi-asserted-by":"crossref","first-page":"A383","DOI":"10.1016\/j.autrev.2009.11.011","article-title":"Geoepidemiology of myasthenia gravis [corrected]","volume":"9","author":"Meyer","year":"2010","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2013.03.005_bb0125","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1212\/01.WNL.0000129702.41868.A5","article-title":"Is \u201cseronegative\u201d MG explained by autoantibodies to MuSK?","volume":"62","author":"Lindstrom","year":"2004","journal-title":"Neurology"},{"key":"10.1016\/j.autrev.2013.03.005_bb0130","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1212\/01.WNL.0000128048.23930.1D","article-title":"Are MuSK antibodies the primary cause of myasthenic symptoms?","volume":"62","author":"Selcen","year":"2004","journal-title":"Neurology"},{"key":"10.1016\/j.autrev.2013.03.005_bb0135","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1172\/JCI21545","article-title":"Induction of myasthenia by immunization against muscle-specific kinase","volume":"116","author":"Shigemoto","year":"2006","journal-title":"J Clin Invest"},{"key":"10.1016\/j.autrev.2013.03.005_bb0140","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.jneuroim.2006.03.016","article-title":"Myasthenia gravis induced in mice by immunization with the recombinant extracellular domain of rat muscle-specific kinase (MuSK)","volume":"175","author":"Jha","year":"2006","journal-title":"J Neuroimmunol"},{"key":"10.1016\/j.autrev.2013.03.005_bb0145","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1196\/annals.1405.002","article-title":"Myasthenia gravis experimentally induced with muscle-specific kinase","volume":"1132","author":"Shigemoto","year":"2008","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.autrev.2013.03.005_bb0150","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1001\/archneurol.2011.2200","article-title":"Acute severe animal model of anti-muscle-specific kinase myasthenia: combined postsynaptic and presynaptic changes","volume":"69","author":"Richman","year":"2012","journal-title":"Arch Neurol"},{"key":"10.1016\/j.autrev.2013.03.005_bb0155","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1002\/ana.21371","article-title":"Anti-MuSK patient antibodies disrupt the mouse neuromuscular junction","volume":"63","author":"Cole","year":"2008","journal-title":"Ann Neurol"},{"key":"10.1016\/j.autrev.2013.03.005_bb0160","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1586\/eci.12.34","article-title":"Muscle autoantibodies in myasthenia gravis: beyond diagnosis?","volume":"8","author":"Meriggioli","year":"2012","journal-title":"Expert Rev Clin Immunol"},{"key":"10.1016\/j.autrev.2013.03.005_bb0165","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1097\/WCO.0b013e328357a829","article-title":"Autoimmune mechanisms in myasthenia gravis","volume":"25","author":"Cavalcante","year":"2012","journal-title":"Curr Opin Neurol"},{"key":"10.1016\/j.autrev.2013.03.005_bb0170","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1097\/WCO.0b013e3283572588","article-title":"Myasthenia and the neuromuscular junction","volume":"25","author":"Gilhus","year":"2012","journal-title":"Curr Opin Neurol"},{"key":"10.1016\/j.autrev.2013.03.005_bb0175","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1126\/science.182.4109.293","article-title":"Neuromuscular junction in myasthenia gravis: decreased acetylcholine receptors","volume":"182","author":"Fambrough","year":"1973","journal-title":"Science"},{"key":"10.1016\/j.autrev.2013.03.005_bb0180","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1212\/WNL.27.4.307","article-title":"Ultrastructural localization of the acetylcholine receptor in myasthenia gravis and in its experimental autoimmune model","volume":"27","author":"Engel","year":"1977","journal-title":"Neurology"},{"key":"10.1016\/j.autrev.2013.03.005_bb0185","first-page":"267","article-title":"Immune complexes (IgG and C3) at the motor end-plate in myasthenia gravis: ultrastructural and light microscopic localization and electrophysiologic correlations","volume":"52","author":"Engel","year":"1977","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.autrev.2013.03.005_bb0190","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1002\/ana.20341","article-title":"Acetylcholine receptors loss and postsynaptic damage in MuSK antibody-positive myasthenia gravis","volume":"57","author":"Shiraishi","year":"2005","journal-title":"Ann Neurol"},{"key":"10.1016\/j.autrev.2013.03.005_bb0195","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1016\/j.ajpath.2011.10.031","article-title":"Antibodies against muscle-specific kinase impair both presynaptic and postsynaptic functions in a murine model of myasthenia gravis","volume":"180","author":"Mori","year":"2012","journal-title":"Am J Pathol"},{"key":"10.1016\/j.autrev.2013.03.005_bb0200","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1093\/brain\/aws025","article-title":"Muscle-specific kinase myasthenia gravis IgG4 autoantibodies cause severe neuromuscular junction dysfunction in mice","volume":"135","author":"Klooster","year":"2012","journal-title":"Brain"},{"key":"10.1016\/j.autrev.2013.03.005_bb0205","series-title":"Myasthenia gravis and myasthenic disorders","first-page":"65","article-title":"Electrodiangosis of endplate diseases","author":"Harper","year":"1999"},{"key":"10.1016\/j.autrev.2013.03.005_bb0210","doi-asserted-by":"crossref","first-page":"2061","DOI":"10.1093\/brain\/awl200","article-title":"Pre- and post-synaptic abnormalities associated with impaired neuromuscular transmission in a group of patients with \u2018limb-girdle myasthenia\u2019","volume":"129","author":"Slater","year":"2006","journal-title":"Brain"},{"key":"10.1016\/j.autrev.2013.03.005_bb0215","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1196\/annals.1405.003","article-title":"Structural factors influencing the efficacy of neuromuscular transmission","volume":"1132","author":"Slater","year":"2008","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.autrev.2013.03.005_bb0220","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1002\/mus.880171208","article-title":"Passive transfer of seronegative myasthenia gravis to mice","volume":"17","author":"Burges","year":"1994","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.autrev.2013.03.005_bb0225","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1002\/mus.21642","article-title":"Pre- and postsynaptic neuromuscular junction abnormalities in musk myasthenia","volume":"42","author":"Niks","year":"2010","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.autrev.2013.03.005_bb0230","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/j.expneurol.2012.01.025","article-title":"Passive and active immunization models of MuSK-Ab positive myasthenia: electrophysiological evidence for pre and postsynaptic defects","volume":"234","author":"Viegas","year":"2012","journal-title":"Exp Neurol"},{"key":"10.1016\/j.autrev.2013.03.005_bb0235","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1038\/nature11348","article-title":"Lrp4 is a retrograde signal for presynaptic differentiation at neuromuscular synapses","volume":"489","author":"Yumoto","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.autrev.2013.03.005_bb0240","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.neuron.2012.04.033","article-title":"Distinct roles of muscle and motoneuron LRP4 in neuromuscular junction formation","volume":"75","author":"Wu","year":"2012","journal-title":"Neuron"},{"issue":"9","key":"10.1016\/j.autrev.2013.03.005_bb0245","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1016\/j.autrev.2013.03.002","article-title":"Serological diagnostics in myasthenia gravis based on novel assays and recently identified antigens","volume":"12","author":"Zisimopoulou","year":"2013","journal-title":"Autoimmun. Rev"},{"key":"10.1016\/j.autrev.2013.03.005_bb0250","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.jneuroim.2008.01.013","article-title":"Clinical fluctuations in MuSK myasthenia gravis are related to antigen-specific IgG4 instead of IgG1","volume":"195","author":"Niks","year":"2008","journal-title":"J Neuroimmunol"},{"key":"10.1016\/j.autrev.2013.03.005_bb0255","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1002\/ana.20061","article-title":"Detection and characterization of MuSK antibodies in seronegative myasthenia gravis","volume":"55","author":"McConville","year":"2004","journal-title":"Ann Neurol"},{"key":"10.1016\/j.autrev.2013.03.005_bb0260","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1111\/j.1468-1331.2009.02624.x","article-title":"Epidemiological and immunological profile of muscle-specific kinase myasthenia gravis in Greece","volume":"16","author":"Tsiamalos","year":"2009","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.autrev.2013.03.005_bb0265","first-page":"257","article-title":"Acetylcholine receptor antibody characteristics in myasthenia gravis. I. Patients with generalized myasthenia or disease restricted to ocular muscles","volume":"49","author":"Vincent","year":"1982","journal-title":"Clin Exp Immunol"},{"issue":"9","key":"10.1016\/j.autrev.2013.03.005_bb0270","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1016\/j.autrev.2013.03.003","article-title":"Complement Associated Pathogenic Mechanisms in Myasthenia Gravis","volume":"12","author":"Tuzon","year":"2013","journal-title":"Autoimmun. Rev"},{"key":"10.1016\/j.autrev.2013.03.005_bb0275","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1126\/science.1144603","article-title":"Anti-inflammatory activity of human IgG4 antibodies by dynamic Fab arm exchange","volume":"317","author":"van der Neut Kolfschoten","year":"2007","journal-title":"Science"},{"key":"10.1016\/j.autrev.2013.03.005_bb0280","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1097\/BOR.0b013e3283412fd4","article-title":"What is IgG4? A review of the biology of a unique immunoglobulin subtype","volume":"23","author":"Nirula","year":"2011","journal-title":"Curr Opin Rheumatol"},{"key":"10.1016\/j.autrev.2013.03.005_bb0285","doi-asserted-by":"crossref","first-page":"3217","DOI":"10.1113\/jphysiol.2010.190298","article-title":"Patient autoantibodies deplete postsynaptic muscle-specific kinase leading to disassembly of the ACh receptor scaffold and myasthenia gravis in mice","volume":"588","author":"Cole","year":"2010","journal-title":"J Physiol"},{"key":"10.1016\/j.autrev.2013.03.005_bb0290","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jneuroim.2011.12.005","article-title":"Divalent and monovalent autoantibodies cause dysfunction of MuSK by distinct mechanisms in a rabbit model of myasthenia gravis","volume":"244","author":"Mori","year":"2012","journal-title":"J Neuroimmunol"},{"key":"10.1016\/j.autrev.2013.03.005_bb0295","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1126\/science.1127142","article-title":"The muscle protein Dok-7 is essential for neuromuscular synaptogenesis","volume":"312","author":"Okada","year":"2006","journal-title":"Science"},{"issue":"9","key":"10.1016\/j.autrev.2013.03.005_bb0300","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1016\/j.autrev.2013.03.001","article-title":"Pathophysiology of myasthenia gravis with antibodies to the acetylcholine receptor, muscle-specific kinase and low-density lipoprotein receptor-related protein 4","volume":"12","author":"Verschuuren","year":"2013","journal-title":"Autoimmun. Rev"},{"key":"10.1016\/j.autrev.2013.03.005_bb0305","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1038\/334255a0","article-title":"Regulation of antibody isotype secretion by subsets of antigen-specific helper T cells","volume":"334","author":"Stevens","year":"1988","journal-title":"Nature"},{"key":"10.1016\/j.autrev.2013.03.005_bb0310","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1038\/ni.1923","article-title":"Complement: a key system for immune surveillance and homeostasis","volume":"11","author":"Ricklin","year":"2010","journal-title":"Nat Immunol"},{"issue":"9","key":"10.1016\/j.autrev.2013.03.005_bb0315","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1016\/j.autrev.2013.03.006","article-title":"Novel future therapeutic options in Myasthenia Gravis","volume":"12","author":"Dalakas","year":"2013","journal-title":"Autoimmun. Rev"},{"key":"10.1016\/j.autrev.2013.03.005_bb0320","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.autrev.2007.01.001","article-title":"Therapeutic options in autoimmune myasthenia gravis","volume":"6","author":"Garcia-Carrasco","year":"2007","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2013.03.005_bb0325","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1002\/mus.20515","article-title":"Cholinergic neuromuscular hyperactivity in patients with myasthenia gravis seropositive for MuSK antibody","volume":"34","author":"Punga","year":"2006","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.autrev.2013.03.005_bb0330","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1002\/mus.21319","article-title":"Acetylcholinesterase inhibitors in MG: to be or not to be?","volume":"39","author":"Punga","year":"2009","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.autrev.2013.03.005_bb0335","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1002\/mus.20935","article-title":"Electrophysiological signs and the prevalence of adverse effects of acetylcholinesterase inhibitors in patients with myasthenia gravis","volume":"37","author":"Punga","year":"2008","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.autrev.2013.03.005_bb0340","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1083\/jcb.200307164","article-title":"MuSK is required for anchoring acetylcholinesterase at the neuromuscular junction","volume":"165","author":"Cartaud","year":"2004","journal-title":"J Cell Biol"},{"key":"10.1016\/j.autrev.2013.03.005_bb0345","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1212\/WNL.0b013e318237f660","article-title":"Anti-MuSK autoantibodies block binding of collagen Q to MuSK","volume":"77","author":"Kawakami","year":"2011","journal-title":"Neurology"},{"key":"10.1016\/j.autrev.2013.03.005_bb0350","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1212\/WNL.54.3.603","article-title":"A randomized trial of 3,4-diaminopyridine in Lambert\u2013Eaton myasthenic syndrome","volume":"54","author":"Sanders","year":"2000","journal-title":"Neurology"},{"key":"10.1016\/j.autrev.2013.03.005_bb0355","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1196\/annals.1254.019","article-title":"Pathogenic autoantibodies in the Lambert\u2013Eaton myasthenic syndrome","volume":"998","author":"Lang","year":"2003","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.autrev.2013.03.005_bb0360","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1002\/ana.10518","article-title":"Anti-neuronal nuclear autoantibody type 2: paraneoplastic accompaniments","volume":"53","author":"Pittock","year":"2003","journal-title":"Ann Neurol"},{"key":"10.1016\/j.autrev.2013.03.005_bb0365","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1038\/283570a0","article-title":"Effects of 4-aminopyridine on normal and demyelinated mammalian nerve fibres","volume":"283","author":"Sherratt","year":"1980","journal-title":"Nature"},{"key":"10.1016\/j.autrev.2013.03.005_bb0370","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/S0022-3565(25)22023-7","article-title":"Effects of 4-aminopyridine and 3,4-diaminopyridine on transmitter release at the neuromuscular junction","volume":"227","author":"Thomsen","year":"1983","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.autrev.2013.03.005_bb0375","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1038\/clpt.2009.35","article-title":"Efficacy of 3,4-diaminopyridine and pyridostigmine in the treatment of Lambert\u2013Eaton myasthenic syndrome: a randomized, double-blind, placebo-controlled, crossover study","volume":"86","author":"Wirtz","year":"2009","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.autrev.2013.03.005_bb0380","doi-asserted-by":"crossref","first-page":"36453","DOI":"10.1074\/jbc.M109.075523","article-title":"Aminopyridines potentiate synaptic and neuromuscular transmission by targeting the voltage-activated calcium channel beta subunit","volume":"284","author":"Wu","year":"2009","journal-title":"J Biol Chem"},{"key":"10.1016\/j.autrev.2013.03.005_bb0385","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.jneuroim.2012.02.010","article-title":"3,4-Diaminopyridine improves neuromuscular transmission in a MuSK antibody-induced mouse model of myasthenia gravis","volume":"245","author":"Mori","year":"2012","journal-title":"J Neuroimmunol"}],"container-title":["Autoimmunity Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997213000311?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997213000311?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T21:12:14Z","timestamp":1761599534000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1568997213000311"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,7]]},"references-count":77,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2013,7]]}},"alternative-id":["S1568997213000311"],"URL":"https:\/\/doi.org\/10.1016\/j.autrev.2013.03.005","relation":{},"ISSN":["1568-9972"],"issn-type":[{"value":"1568-9972","type":"print"}],"subject":[],"published":{"date-parts":[[2013,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Mechanisms associated with the pathogenicity of antibodies against muscle-specific kinase in myasthenia gravis","name":"articletitle","label":"Article Title"},{"value":"Autoimmunity Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.autrev.2013.03.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}